Dexamethasone implant shows comparable outcomes in vitrectomized, non-vitrectomized eyes
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — A study found that the efficacy and safety of the Ozurdex implant for diabetic macular edema are comparable in vitrectomized vs. non-vitrectomized eyes.
“Efficacy was not influenced by full vitrectomy for diabetic retinopathy complications, and the safety profile was well balanced between groups,” Matias Iglicki, MD, said at the Retina World Congress.
The VITDEX study was conducted by the International Retina Group, a collaborative network of specialists from 14 countries around the world. The aim was to compare the visual and anatomical outcomes in vitrectomized and non-vitrectomized eyes treated with Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) for DME.
“In DME, we have the ischemic and inflammatory components, and we were wondering, does the vitreous or the lack of vitreous impact the implant’s efficacy and safety profile?” Iglicki said.
The baseline characteristics of the two groups of 130 non-vitrectomized eyes and 106 vitrectomized eyes included in the study were well balanced, and the outcomes following implantation of the dexamethasone implant were comparable.
“We found no statistically significant difference neither in [visual acuity] changes nor in [central subfield thickness] changes between the two groups. The safety profile was comparable. No significant difference was found in BCVA or OCT measurements,” he said.
This paper opens up the door to a randomized clinical trial on the impact of vitrectomy in these patients, which will add more significant data to these findings, he said.
Collapse
Iglicki M, et al. The VITDEX study: Vitrectomized vs. non-vitrectomized patients and DEX implant results. Presented at: Retina World Congress; May 12-15, 2022; Fort Lauderdale, Fla.
Read more about
Click Here to Manage Email Alerts